Shares of Laurus Labs rose 3.3 percent intraday on September 5 after company received establishment inspection report from US Food and Drug Administration (USFDA).
The company said in a press release that it received the establishment inspection report (EIR) from USFDA for its API units 1& 3 at Parawada, Visakhapatnam, for the inspection conducted in June.
Also, in FDF segment the company received global fund expert review panel approval for fixed dose combination TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF-funded projects.
Laurus Labs is the three companies to receive the approval for this antiretroviral therapy product.
At 1049 hours, Laurus Labs was quoting at Rs 335.00, up Rs 8.50, or 2.60 percent, on the BSE.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
